Global Castrate-resistant Prostate Cancer Market size was valued at US$ 10.93 Bn in 2022 and the total revenue is expected to grow at 8.4 % through 2022 to 2029, reaching nearly US$ 19.23 Bn.Global Castrate-resistant Prostate Cancer Market Overview:
Prostate cancer that has to convert impervious to hormone treatment is known as castrate-resistant prostate cancer. Hormone treatment, commonly known as androgen deprivation therapy (ADT), reduces testosterone levels in the body significantly. The levels of testosterone are similar to those found in men who have had their testicles surgically removed.To know about the Research Methodology :- Request Free Sample Report
Global Castrate-resistant Prostate Cancer Market Dynamics:
The increased prevalence of castrate-resistant prostate cancer, as well as the increasing acceptance of new medicines and an unhealthy lifestyle, are expected to drive market expansion. The market's growth rate is also fueled by the need for rapid alternative treatments and major companies' expenditures in R&D. The high frequency of prostate cancer that evolves into castrate-resistant prostate cancer within a few years after diagnosis is causing a rise in the prevalence of castrate-resistant prostate cancer across the world. In the US, over 3.6 million men were diagnosed with prostate cancer in 2020, with a 12.2 % occurrence for metastatic castrate-resistant prostate cancer (mCRPC). The growing trend of early diagnosis of the disease is linked to a better prognosis. Hence, these factors are likely to motivate market expansion. Further, 85.0% of demographics had a favorable response to conventional chemical castration therapy during the first session. Furthermore, the availability of patient-friendly healthcare expenditures like health insurance offered by various firms is probable to enhance the market for castrate-resistant prostate cancer. Another issue affecting the development of the segments is the lack of a consistent treatment sequence. Treatment options vary greatly based on the patient's features and the physician's inclination. These factors are expected to influence the growth of the castrate-resistant prostate cancer market.Global Castrate-resistant Prostate Cancer Market Segment Analysis:
The Hormonal Therapy segment is anticipated to adhere to the growth of the Castrate-resistant Prostate Cancer Market. The hormonal therapy segment is likely to dominate the growth of the market with 83.1% of revenue share in 2019. Owing to the rise in aging people, which are more susceptible to castrate-resistant prostate cancer, the launch of new medications, the availability of a large number of authorized drugs, and the extension of product indications are the key drivers driving the hormonal therapy segment's growth. Furthermore, the market for castrate-resistant prostate cancer is expected to rise due to the increasing development of novel medicines to meet unmet requirements and existing treatment choices. Sir Mortimer B. Davis Jewish General Hospital is currently conducting a phase II clinical trial with a new generation of hormonal therapy Darolutamide (BAY1841788) to assess the response of stereotactic body radiation therapy (SBRT) layered on Darolutamide (BAY1841788) on radiological progression-free survival (RPFS) and deferring palliative second line symptoms. The investigation started in October 2020 and is scheduled to end in November 2027. As a result, the market is anticipated to rise as research and development efforts increase, as well as the increased prevalence of castrate-resistant prostate cancer due to the aging population projected to motivate market expansion.Global Castrate-resistant Prostate Cancer Market Regional Segment:
North America is likely to dominate the market growth and held a market share of 46.1% in 2020, the key factors attributing to the growth of the market are the high incidence of the conditions, the existence of key market participants, and growing research and development activities. The US is estimated to lead the market growth in North America owing to advantageous reimbursement policies offered by the government. Jevtana, for example, is covered under Medicare Part B coverage. J9043 and C9276 are the codes for it in the Healthcare Common Procedure Coding System. As a result of the aforementioned reasons, the US market is anticipated to be one of the largest and continue to expand in the future. Further, mergers and collaborations are supporting the growth of the region for instance, in June 2020, Exelixis, Inc., signed a partnership with Roche-Genentech and Takeda, to launch a phase III clinical study in men with metastatic castration-resistant prostate cancer to assess the safety and effectiveness of cabozantinib in combination with atezolizumab (mCRPC). Hence, the factor is likely to create more opportunities for the budding key players to enter the market. The objective of the report is to present a comprehensive analysis of the Global Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding the Global Market dynamics, structure by analyzing the market segments and project the Global Castrate-resistant Prostate Cancer Market size. Clear representation of competitive analysis of key players by Grade, price, financial position, Grade portfolio, growth strategies, and regional presence in the Global Market make the report investor’s guide.Global Castrate-resistant Prostate Cancer Market Scope: Inquire before buying
Global Castrate-resistant Prostate Cancer Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 10.93 Bn. Forecast Period 2023 to 2029 CAGR: 8.4% Market Size in 2029: US $ 19.23 Bn. Segments Covered: by Product Chemotherapy Hormonal Therapy Immunotherapy Radiotherapy Global Castrate-resistant Prostate Cancer Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Global Castrate-resistant Prostate Cancer Market Key Players
1.Gilead Sciences, Inc. 2. Active Biotech 3. Diagnocure 4. Glaxosmithkline 5. Northwest Biotherapeutics 6. Millennium Pharmaceuticals 7. Hologic 8. Spectrum Pharmaceuticals 9. Abbott Laboratories 10.Bayer Healthcare Pharmaceuticals 11.Sanofi 12.Johnson & Johnson Services, Inc. 13.Pfizer, Inc. 14.Astellas Pharma, Inc. 15.Bayer AG FAQs: 1. What is the global Castrate-resistant Prostate Cancer Market value in 2022? Ans: The global Castrate-resistant Prostate Cancer Market value in 2022 was estimated as 10.93 Billion USD. 2. What is the global Castrate-resistant Prostate Cancer Market growth? Ans: The global Castrate-resistant Prostate Cancer Market is anticipated to grow with a CAGR of 8.4% in the forecast period and is likely to reach USD 19.23 Billion by the end of 2029. 3. Which Therapy segment is expected to dominate the global Castrate-resistant Prostate Cancer Market during the forecast period? Ans: Hormonal therapy dominated the castrate-resistant prostate cancer market with a revenue share of 83.1% in 2019. This is attributable to the increasing market penetration of Xtandi (enzalutamide) and the launch of Erleada (apalutamide) in the U.S., Europe, & Japan. 4. Which region is expected to dominate the global Castrate-resistant Prostate Cancer Market during the forecast period? Ans: North America dominated the Castrate-resistant Prostate Cancer market with a share of 46.1 % in 2022. This growth is attributable to a high prevalence of the disease, the presence of regional players, and favorable reimbursement policies. Changing lifestyle is another factor adding to the prevalence of diseases. 5. What is the key driving factor for the growth of the global Castrate-resistant Prostate Cancer Market? Ans: Key factors that are driving the castrate-resistant prostate cancer market growth include the increasing global burden of castrate-resistant prostate cancer, supported by an unhealthy lifestyle, improved treatment options, and advancement in research and development studies.
1. Preface 1.1. Market Definition and Key Research Objectives 1.2. Research Highlights 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Technology 2.3.2. Primary Research 2.3.2.1. Data from Primary Technology 2.3.2.2. Breakdown of Primary Technology 3. Executive Summary: Global Castrate-resistant Prostate Cancer Market Size, by Market Value (US$ Bn) 3.1. Global Market Segmentation 3.2. Global Market Segmentation Share Analysis, 2022 3.2.1. Global 3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 3.3. Geographical Snapshot of the Castrate-resistant Prostate CancerMarket 3.4. Geographical Snapshot of the Castrate-resistant Prostate CancerMarket, By Manufacturer share 4. Global Castrate-resistant Prostate Cancer Market Overview, 2022-2029 4.1. Market Dynamics 4.1.1. Drivers 4.1.1.1. Global 4.1.1.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.2. Restraints 4.1.2.1. Global 4.1.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.3. Opportunities 4.1.3.1. Global 4.1.3.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.4. Challenges 4.1.4.1. Global 4.1.4.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.5. Industry Trends and Emerging Technologies 4.1.6. Porter Five Forces Analysis 4.1.6.1. Threat of New Entrants 4.1.6.2. Bargaining Power of Buyers/Consumers 4.1.6.3. Bargaining Power of Suppliers 4.1.6.4. Threat of Substitute Grades 4.1.6.5. Intensity of Competitive Rivalry 4.1.7. Value Chain Analysis 4.1.8. Technological Roadmap 4.1.9. Regulatory landscape 4.1.10. Impact of the Covid-19 Pandemic on the Global Castrate-resistant Prostate Cancer Market 5. Supply Side and Demand Side Indicators 6. Global Castrate-resistant Prostate Cancer Market Analysis and Forecast, 2022-2029 6.1. Global Castrate-resistant Prostate Cancer Market Size & Y-o-Y Growth Analysis. 7. Global Castrate-resistant Prostate Cancer Market Analysis and Forecasts, 2022-2029 7.1. Market Size (Value) Estimates & Forecast By Therapy, 2022-2029 7.1.1. Chemotherapy 7.1.2. Hormonal Therapy 7.1.3. Immunotherapy 7.1.4. Radiotherapy 8. Global Castrate-resistant Prostate Cancer Market Analysis and Forecasts, By Region 8.1. Market Size (Value) Estimates & Forecast By Region, 2022-2029 8.1.1. North America 8.1.2. Europe 8.1.3. Asia-Pacific 8.1.4. Middle East & Africa 8.1.5. South America 9. North America Castrate-resistant Prostate Cancer Market Analysis and Forecasts, 2022-2029 9.1. Market Size (Value) Estimates & Forecast By Therapy, 2022-2029 9.1.1. Chemotherapy 9.1.2. Hormonal Therapy 9.1.3. Immunotherapy 9.1.4. Radiotherapy 10. North America Castrate-resistant Prostate Cancer Market Analysis and Forecasts, By Country 10.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029 10.1.1. US 10.1.2. Canada 10.1.3. Mexico 11. U.S. Castrate-resistant Prostate Cancer Market Analysis and Forecasts, 2022-2029 11.1. Market Size (Value) Estimates & Forecast By Therapy’s, 2022-2029 12. Canada Castrate-resistant Prostate Cancer Market Analysis and Forecasts, 2022-2029 12.1. Market Size (Value) Estimates & Forecast By Therapy’s, 2022-2029 13. Mexico Castrate-resistant Prostate Cancer Market Analysis and Forecasts, 2022-2029 13.1. Market Size (Value) Estimates & Forecast By Therapy’s, 2022-2029 14. Europe Castrate-resistant Prostate Cancer Market Analysis and Forecasts, 2022-2029 14.1. Market Size (Value) Estimates & Forecast By Therapy’s, 2022-2029 15. Europe Castrate-resistant Prostate Cancer Market Analysis and Forecasts, By Country 15.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029 15.1.1. U.K 15.1.2. France 15.1.3. Germany 15.1.4. Italy 15.1.5. Spain 15.1.6. Sweden 15.1.7. CIS Countries 15.1.8. Rest of Europe 16. U.K Castrate-resistant Prostate Cancer Market Analysis and Forecasts, 2022-2029 16.1. Market Size (Value) Estimates & Forecast By Therapy’s, 2022-2029 17. France Castrate-resistant Prostate Cancer Market Analysis and Forecasts, 2022-2029 17.1. Market Size (Value) Estimates & Forecast By Therapy’s, 2022-2029 18. Germany Castrate-resistant Prostate Cancer Market Analysis and Forecasts, 2022-2029 18.1. Market Size (Value) Estimates & Forecast By Therapy’s, 2022-2029 19. Italy Castrate-resistant Prostate Cancer Market Analysis and Forecasts, 2022-2029 19.1. Market Size (Value) Estimates & Forecast By Therapy’s, 2022-2029 20. Spain Castrate-resistant Prostate Cancer Market Analysis and Forecasts, 2022-2029 20.1. Market Size (Value) Estimates & Forecast By Therapy’s, 2022-2029 21. Sweden Castrate-resistant Prostate Cancer Market Analysis and Forecasts, 2022-2029 21.1. Market Size (Value) Estimates & Forecast By Therapy’s, 2022-2029 22. CIS Countries Castrate-resistant Prostate Cancer Market Analysis and Forecasts, 2022-2029 22.1. Market Size (Value) Estimates & Forecast By Therapy’s, 2022-2029 23. Rest of Europe Castrate-resistant Prostate Cancer Market Analysis and Forecasts, 2022-2029 23.1. Market Size (Value) Estimates & Forecast By Therapy’s, 2022-2029 24. Asia Pacific Castrate-resistant Prostate Cancer Market Analysis and Forecasts, 2022-2029 24.1. Market Size (Value) Estimates & Forecast By Therapy’s, 2022-2029 25. Asia Pacific Castrate-resistant Prostate Cancer Market Analysis and Forecasts, by Country 25.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029 25.1.1. China 25.1.2. India 25.1.3. Japan 25.1.4. South Korea 25.1.5. Australia 25.1.6. ASEAN 25.1.7. Rest of Asia Pacific 26. China Castrate-resistant Prostate Cancer Market Analysis and Forecasts, 2022-2029 26.1. Market Size (Value) Estimates & Forecast By Therapy’s, 2022-2029 27. India Castrate-resistant Prostate Cancer Market Analysis and Forecasts, 2022-2029 27.1. Market Size (Value) Estimates & Forecast By Therapy’s, 2022-2029 28. Japan Castrate-resistant Prostate Cancer Market Analysis and Forecasts, 2022-2029 28.1. Market Size (Value) Estimates & Forecast By Therapy’s, 2022-2029 29. South Korea Castrate-resistant Prostate Cancer Market Analysis and Forecasts, 2022-2029 29.1. Market Size (Value) Estimates & Forecast By Therapy’s, 2022-2029 30. Australia Castrate-resistant Prostate Cancer Market Analysis and Forecasts, 2022-2029 30.1. Market Size (Value) Estimates & Forecast By Therapy’s, 2022-2029 31. ASEAN Castrate-resistant Prostate Cancer Market Analysis and Forecasts, 2022-2029 31.1. Market Size (Value) Estimates & Forecast By Therapy’s, 2022-2029 32. Rest of Asia Pacific Castrate-resistant Prostate Cancer Market Analysis and Forecasts, 2022-2029 32.1. Market Size (Value) Estimates & Forecast By Therapy’s, 2022-2029 33. Middle East Africa Castrate-resistant Prostate Cancer Market Analysis and Forecasts, 2022-2029 33.1. Market Size (Value) Estimates & Forecast By Therapy’s, 2022-2029 34. Middle East Africa Castrate-resistant Prostate Cancer Market Analysis and Forecasts, by Country 34.1. Market Size (Value) Estimates & Forecast by Country, 2022-2029 34.1.1. South Africa 34.1.2. GCC Countries 34.1.3. Egypt 34.1.4. Nigeria 34.1.5. Rest of ME&A 35. South Africa Castrate-resistant Prostate Cancer Market Analysis and Forecasts, 2022-2029 35.1. Market Size (Value) Estimates & Forecast By Therapy’s, 2022-2029 36. GCC Countries Castrate-resistant Prostate Cancer Market Analysis and Forecasts, 2022-2029 36.1. Market Size (Value) Estimates & Forecast By Therapy’s, 2022-2029 37. Egypt Castrate-resistant Prostate Cancer Market Analysis and Forecasts, 2022-2029 37.1. Market Size (Value) Estimates & Forecast By Therapy’s, 2022-2029 38. Nigeria Castrate-resistant Prostate Cancer Market Analysis and Forecasts, 2022-2029 38.1. Market Size (Value) Estimates & Forecast By Therapy’s, 2022-2029 39. Rest of ME&A Castrate-resistant Prostate Cancer Market Analysis and Forecasts, 2022-2029 39.1. Market Size (Value) Estimates & Forecast By Therapy’s, 2022-2029 40. South America Castrate-resistant Prostate Cancer Market Analysis and Forecasts, 2022-2029 40.1. Market Size (Value) Estimates & Forecast By Therapy’s, 2022-2029 41. South America Castrate-resistant Prostate Cancer Market Analysis and Forecasts, by Country 41.1. Market Size (Value) Estimates & Forecast by Country, 2022-2029 41.1.1. Brazil 41.1.2. Argentina 41.1.3. Rest of South America 42. Brazil Castrate-resistant Prostate Cancer Market Analysis and Forecasts, 2022-2029 42.1. Market Size (Value) Estimates & Forecast By Therapy’s, 2022-2029 43. Argentina Castrate-resistant Prostate Cancer Market Analysis and Forecasts, 2022-2029 43.1. Market Size (Value) Estimates & Forecast By Therapy’s, 2022-2029 44. Rest of South America Castrate-resistant Prostate Cancer Market Analysis and Forecasts, 2022-2029 44.1. Market Size (Value) Estimates & Forecast By Therapy’s, 2022-2029 45. Competitive Landscape 45.1. Geographic Footprint of Major Players in the Castrate-resistant Prostate Cancer Market 45.2. Competition Matrix 45.2.1. Competitive Benchmarking of Key Players By Price, Presence, Market Share, Fiber Grades, and R&D Investment 45.2.2. New Grade Launches and Grade Enhancements 45.2.3. Market Consolidation 45.2.3.1. M&A by Regions, Investment, and Verticals 45.2.3.2. M&A, Forward Integration and Backward Integration 45.2.3.3. Partnership, Joint Ventures, and Strategic Alliances/ Sales Agreements 45.3. Company Profile: Key Players 45.3.1. Biozeus Biopharmaceuticals. 45.3.1.1. Company Overview 45.3.1.2. Financial Overview 45.3.1.3. Geographic Footprint 45.3.1.4. Grade Portfolio 45.3.1.5. Business Strategy 45.3.1.6. Recent Developments 45.3.2. Gilead Sciences, Inc. 45.3.3. Active Biotech 45.3.4. Diagnocure 45.3.5. Glaxosmithkline 45.3.6. Northwest Biotherapeutics 45.3.7. Millennium Pharmaceuticals 45.3.8. Hologic 45.3.9. Spectrum Pharmaceuticals 45.3.10. Abbott Laboratories 45.3.11. Bayer Healthcare Pharmaceuticals 45.3.12. Sanofi 45.3.13. Johnson & Johnson Services, Inc. 45.3.14. Pfizer, Inc. 45.3.15. Astellas Pharma, Inc. 45.3.16. Bayer AG Primary Key Insights